Mikhail Dvorkin

Researcher Next ID · RN-013560

Researcher · Medicine

, Russia

Not currently recruitingFunding unknown

Research interests

Medicine

Biochemistry, Genetics and Molecular Biology

Lung Cancer Research Studies

Lung Cancer Treatments and Mutations

Cancer Immunotherapy and Biomarkers

Cancer Genomics and Diagnostics

Gastric Cancer Management and Outcomes

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
The Lancet · 2023 · 10.1016/s0140-6736(23)00961-3
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30539-8
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30539-8
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
The Lancet · 2019 · 10.1016/s0140-6736(19)32222-6
SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing
Journal of Computational Biology · 2012 · 10.1089/cmb.2012.0021

No projects listed.